[HTML][HTML] Nivolumab versus everolimus in advanced renal-cell carcinoma
RJ Motzer, B Escudier, DF McDermott… - … England Journal of …, 2015 - Mass Medical Soc
Background Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated
with encouraging overall survival in uncontrolled studies involving previously treated …
with encouraging overall survival in uncontrolled studies involving previously treated …
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long‐term follow‐up of the randomized, open‐label, phase 3 …
Background CheckMate 025 has shown superior efficacy for nivolumab over everolimus in
patients with advanced renal cell carcinoma (aRCC) along with improved safety and …
patients with advanced renal cell carcinoma (aRCC) along with improved safety and …
CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma
B Escudier, P Sharma, DF McDermott, S George… - European urology, 2017 - Elsevier
Abstract Background The randomized, phase 3 CheckMate 025 study of nivolumab (n= 410)
versus everolimus (n= 411) in previously treated adults (75% male; 88% white) with …
versus everolimus (n= 411) in previously treated adults (75% male; 88% white) with …
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a …
V Heinemann, U Vehling-Kaiser, D Waldschmidt… - Gut, 2013 - gut.bmj.com
Objective AIO-PK0104 investigated two treatment strategies in advanced pancreatic cancer
(PC): a reference sequence of gemcitabine/erlotinib followed by 2nd-line capecitabine was …
(PC): a reference sequence of gemcitabine/erlotinib followed by 2nd-line capecitabine was …
[HTML][HTML] Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non–small-cell lung Cancer treated with Pemetrexed
DC Christoph, BR Asuncion, B Hassan, C Tran… - Journal of thoracic …, 2013 - Elsevier
Introduction: Folate receptor alpha (FRA) regulates cellular uptake of folates and antifolates.
Information about FRA protein expression in metastatic non–small-cell lung cancer (NSCLC) …
Information about FRA protein expression in metastatic non–small-cell lung cancer (NSCLC) …
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the …
Purpose Treatment options for patients with platinum-refractory recurrent or metastatic
squamous cell carcinoma of the head and neck (R/M SCCHN) are limited. The purpose of …
squamous cell carcinoma of the head and neck (R/M SCCHN) are limited. The purpose of …
[HTML][HTML] Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer …
F Breitenbuecher, S Hoffarth, K Worm, D Cortes-Incio… - PLoS …, 2014 - journals.plos.org
Background Oncogenic mutations are powerful predictive biomarkers for molecularly
targeted cancer therapies. For mutation detection patients have to undergo invasive tumor …
targeted cancer therapies. For mutation detection patients have to undergo invasive tumor …
[HTML][HTML] Circulating tumor cell composition in renal cell carcinoma
I Nel, TC Gauler, K Bublitz, L Lazaridis, A Goergens… - PloS one, 2016 - journals.plos.org
Purpose Due to their minimal-invasive yet potentially current character circulating tumor
cells (CTC) might be useful as a “liquid biopsy” in solid tumors. However, successful …
cells (CTC) might be useful as a “liquid biopsy” in solid tumors. However, successful …
[HTML][HTML] pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104
S Ormanns, JT Siveke, V Heinemann, M Haas, B Sipos… - BMC cancer, 2014 - Springer
Background The role of pERK, pAKT and p53 as biomarkers in patients with advanced
pancreatic cancer has not yet been defined. Methods Within the phase III study AIO-PK0104 …
pancreatic cancer has not yet been defined. Methods Within the phase III study AIO-PK0104 …
[HTML][HTML] Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural …
DC Christoph, BR Asuncion, C Mascaux, C Tran… - Journal of thoracic …, 2012 - Elsevier
Background: Pemetrexed-based chemotherapy represents the standard of care in first-line
treatment of advanced malignant pleural mesothelioma (MPM). However, there are no …
treatment of advanced malignant pleural mesothelioma (MPM). However, there are no …